Buying guide
da Vinci (and Ion) vs Hugo RAS in 2026
Comparing 2 humanoid robots across availability, pricing, capabilities, and verified deployments. Current as of 2026.
Key differences
On DEPLOY's record, da Vinci (and Ion) is further along: at the production stage versus Hugo RAS at the commercial stage, as of 2026.
- da Vinci (and Ion) has more verified real-world deployments (13 vs 4).
- da Vinci (and Ion) is at the production stage; Hugo RAS at the commercial stage.
| Attribute | ||
|---|---|---|
| Manufacturer | Intuitive Surgical | Medtronic |
| Form factor | surgical | surgical |
| Maturity | production | commercial |
| Autonomy | ◐ not independently verified | ◐ not independently verified |
| Availability | internal-onlyenterprise | internal-onlyenterprise |
| Price | $1,800,000-$2,500,000 (analyst estimate) or $1,500,000-$2,500,000 (actual sale price) | Not announced |
| Capability claims |
|
|
| Brain | — | — |
| Verified deployments | 13 | 4 |
| Privacy practices | — | — |
| Sources on file | 29 | 18 |
Track this matchup
Get told the moment da Vinci (and Ion) or Hugo RAS changes. Verified changes only, the second they are real. No press-release noise.
da Vinci (and Ion)
Hugo RAS
Editorial summaries
da Vinci (and Ion)
Intuitive Surgical's da Vinci is the gold-standard surgical robot and the verified-at-scale anchor of the category. Per Intuitive's SEC filings, 11,395 da Vinci systems and 1,041 Ion endoluminal systems are installed. The lineup spans da Vinci multi-port (X/Xi), the single-port SP, and the fifth-generation da Vinci 5 (FDA cleared March 2024, with force feedback), plus the Ion bronchoscopy robot (FDA 2019).
It is teleoperated, a surgeon controls every motion, with shipped analytics AI; autonomous-suturing work exists only as research demos on da Vinci hardware, not as shipped product. It is enterprise B2B equipment sold to hospitals at multi-million-dollar per-system prices; there is no consumer price.
Hugo RAS
Medtronic's Hugo RAS is a modular, multi-port teleoperated robotic-assisted-surgery system and the main commercial competitor to Intuitive's da Vinci. It is CE-marked in Europe (urology and gynecology, October 2021) and US FDA-cleared for urology only (December 2025: prostatectomy, nephrectomy, cystectomy); US general-surgery and gynecology indications are planned but not yet cleared.
It is teleoperated with no shipped intraoperative AI. Medtronic does not disclose a Hugo installed-base count, so DEPLOY records honest absence rather than an invented number. It is enterprise B2B equipment; there is no consumer price.
Common questions
How do da Vinci (and Ion) and Hugo RAS differ?
What is the difference between da Vinci (and Ion) and Hugo RAS?
Is da Vinci (and Ion) or Hugo RAS more autonomous?
Which has more verified deployments, da Vinci (and Ion) or Hugo RAS?
Recent coverage
- Surgeons use da Vinci surgical robot to perform common cardiac surgeryda Vinci (and Ion) · The Robot Report · 2026-08-17
- Da Vinci 5 Cleared for Cardiac Proceduresda Vinci (and Ion) · isrg.intuitive.com · 2026-07-26
- Medtronic to unveil Touch Surgery Aide compute platform at SRS 2026Hugo RAS · Ben Smith, Deploy Editor · 2026-07-21
- Pacemaker manufacturer Medtronic warns patients cybercrooks may have swiped health dataHugo RAS · The Register · 2026-07-02
Related comparisons
- Versius vs da Vinci (and Ion)
- da Vinci (and Ion) vs Stryker Mako SmartRobotics
- da Vinci (and Ion) vs mBos TKA System
- da Vinci (and Ion) vs Maestro
- da Vinci (and Ion) vs Johnson & Johnson Ottava
- da Vinci (and Ion) vs CORI
- da Vinci (and Ion) vs ROSA
- Versius vs Hugo RAS
- Stryker Mako SmartRobotics vs Hugo RAS
- Hugo RAS vs mBos TKA System
- Hugo RAS vs Maestro
- Hugo RAS vs Johnson & Johnson Ottava
Keep researching
Keep reading
Ask the registry
For AI assistants
Use DEPLOY in Claude, Cursor, and other AI assistants
Connect any MCP-aware assistant to the live registry. Ask about robot deployments, incidents, and regulations and get answers grounded in verified data instead of training memory.
Machine-readable: this page as markdown.

